InDex Pharmaceuticals competitorsClear all

InDex Pharmaceuticals's top competitors include GT Biopharma, Humanigen, Selecta Biosciences and Relypsa.
InDex Pharmaceuticals
InDex Pharmaceuticals
InDex Pharmaceuticals Holding is a company that focuses on immunological diseases.
GT Biopharma
GT Biopharma
GT Biopharma (formerly Oxis International) is engaged in the development of immunotherapies for cancer treatment.
Humanigen
Humanigen
Humanigen is repositioning and developing its proprietary monoclonal antibodies to meet some critical unmet needs in cancer science.
Selecta Biosciences
Selecta Biosciences
Selecta is a clinical-stage biopharmaceutical company advancing a pipeline of differentiated products designed to modulate the immune system.
Relypsa
Relypsa
Relypsa is a biopharmaceutical company developing drugs for treating cardiovascular and renal diseases.
Founding Date
Founding Date
2000
Founding Date
1965
Founding Date
2000
Founding Date
2008
Founding Date
2007
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Subsidiary
Tags
Locations
Locations
HQ
Locations
Tampa, US HQ
Beverly Hills, US
Locations
Burlingame, US HQ
Locations
Watertown, US HQ
Locations
Redwood City, US HQ
Employees
Employees
7
Employees
340% decrease
Employees
233% decrease
Employees
3939% decrease
Employees
3241% decrease
Valuation ($)
Valuation ($)
61.9 m
Valuation ($)
9.5 m
Valuation ($)
1.1 b
Valuation ($)
229.2 m
Valuation ($)
N/A
Twitter followers
Twitter followers
249
Twitter followers
66
Twitter followers
N/A
Twitter followers
360
Twitter followers
503
Alexa Website Rank
Alexa Website Rank
N/A
Alexa Website Rank
379858
Alexa Website Rank
274974
Alexa Website Rank
439132
Alexa Website Rank
529317
Employee Rating
Employee Rating
N/A
Employee Rating
N/A
Employee Rating
3
Employee Rating
3.6
Employee Rating
3.1

Financial

Net income
Net income
N/A
Net income
($38.6m) (FY, 2019)
Net income
($10.3m) (FY, 2019)
Net income
($55.4m) (FY, 2019)
Net income
($178.7m) (FY, 2015)

Funding

Total funding raised
Total funding raised
$ 31.9m
Total funding raised
$ 1.4m
Total funding raised
$ 131.7m
Total funding raised
$ 167.7m
Total funding raised
$ 352.3m
For sources of this data, please see the company profile

View company profiles

GT Biopharma
HQ
Tampa, US
Employees
3↓ 40% decrease

GT Biopharma (formerly Oxis International) is engaged in the development of immunotherapies for cancer treatment.

View company
Humanigen
HQ
Burlingame, US
Employees
2↓ 33% decrease

Humanigen is repositioning and developing its proprietary monoclonal antibodies to meet some critical unmet needs in cancer science.

View company
Selecta Biosciences
HQ
Watertown, US
Employees
39↓ 39% decrease

Selecta is a clinical-stage biopharmaceutical company advancing a pipeline of differentiated products designed to modulate the immune system.

View company
Relypsa
HQ
Redwood City, US

Relypsa is a biopharmaceutical company developing drugs for treating cardiovascular and renal diseases.

View company